,

PhD Project in A novel intervention to support myelin regeneration and functional outcomes in Multiple Sclerosis. (Closing Date: 25 Aug 2023

Status: Opening

Applications open: 7/07/2023
Applications close: 25/08/2023

About this scholarship

 

Multiple sclerosis (MS) is characterised by recurrent, or progressive demyelination (loss of the protective myelin sheath) of nerve fibres of the central nervous system. Degeneration of the nerve axons markedly accelerates neuronal function loss and negatively affects motor function, leading to morbidity and premature death.
Available disease-modifying therapies (DMTs) are primarily designed to prevent further myelin injury in MS, so the contemporary therapeutic priority is to discover strategies to restore myelin. We have developed a commercial-in-confidence therapeutic formulation of pure alkylglycerols. We have shown that this oral formulation completely preserves myelin integrity and locomotor function in murine models of aggressive demyelination. Alkylglycerols are naturally occurring ether-lipids rich in mammalian milk and serve as substrate precursor for plasmalogens. In myelin membrane, plasmalogens serve as the key lipid providing insulatory function that enables nerve-signal transduction.

Through this research, we propose to establish a pilot randomised control trial to test the efficacy of a commercially available enriched alkylglycerol formulation in Australians at first presentation of demyelinating disease or early MS, to support myelin homeostasis, promote remyelination and improve clinical outcomes. Primary endpoint outcomes measures will include state-of-the-art quantitative magnetic resonance imaging of cerebral/spinal myelin and physical disability. Secondary objective measures will include psychosocial considerations (quality of life, fatigue, cognition) and blood biomarkers of disease activity, neuroaxonal damage and treatment response.

To study the efficacy of formulated alkylglycerols, provided orally, in improving outcomes for patients at first presentation of demyelinating disease via a double-blind randomised placebo controlled phase II trial. Our broader hypothesis predicts that alkylglycerol therapy will enhance the process of remyelination in MS and thereby improve clinical outcomes (i.e., clinical disability; fatigue; quality of life). Response to treatment over a 18-month intervention period will be assessed by:

  • Primary outcomes of brain and spinal MRI scans (characterise recurrent demyelinating events / remyelination); clinical assessment of functional ability (disability indices) and cognition.
  • Additional outcomes measures of quality of life and blood biomarkers associated with clinical and MRI-related measures of MS disease activity and neuroaxonal damage.

Primary outcome measures are:
1. brain and spinal MRI scans (characterise recurrent demyelinating events / remyelination).
2. clinical assessment of functional ability (disability indices) and cognition.
3. Additional outcomes measures of quality of life and blood biomarkers associated with clinical and MRI-related measures of MS disease activity and neuroaxonal damage.

Alkylglycerols are naturally occurring compounds that are safe to consume and well-tolerated, providing potentially, a new disease modifying therapy opportunity that can be fast-tracked into clinical practice for treatment of early MS.

This project may provide an Internship opportunity. The direct research costs for this project are funded by MSWA, who in partnership with the Neurologist Professor Alan Kermode (Perron Neuro Trans Res Institute) will provide in situ experience with people living with MS. The candidate will also have an opportunity to gain experience with residential care patients hosted by MSWA, in Albany, which will serve as a regional referral centre.

 

  • Future Students

  • Faculty of Health Sciences

  • Higher Degree by Research

  • Australian Citizen
  • Australian Permanent Resident
  • New Zealand Citizen
  • Permanent Humanitarian Visa
  • International Student

  • Merit Based
 

The annual scholarship package (stipend and tuition fees) is approx. $60,000 – $70,000 p.a.

Successful HDR applicants for admission will receive a 100% fee offset for up to 4 years, stipend scholarships at the 2023 RTP rate valued at $32,250 p.a. for up to a maximum of 3 years, with a possible 6 month completion scholarship. Applicants are determined via a competitive selection process and will be notified of the scholarship outcome in November 2023.

For detailed information, visit: https://direshopping.com/product/presidential-scholarship-at-concordia-university-golden-opportunity-for-students/

 

Scholarship Details

1

 

All applicable HDR courses

 

 

A PhD student undertaking a pilot clinical trial investigating the efficacy of alkylglycerols in multiple sclerosis should possess a preferable skill set. This includes a foundation in clinical research methodologies, knowledge of multiple sclerosis pathophysiology, familiarity with regulatory requirements, proficiency in data analysis and excellent communication skills. Additionally, the student should demonstrate critical thinking abilities, attention to detail, adaptability and the capacity to work collaboratively within a multidisciplinary team. These skills would enable the student to design and execute the trial effectively, analyze and interpret the results accurately, and contribute meaningfully to the advancement of knowledge in the field of multiple sclerosis research.

 

 

Application process

 

If this project excites you, and your research skills and experience are a good fit for this specific project, you should contact the Project Lead (listed below in the enquires section) via the https://forms.curtin.edu.au/Produce/wizard/791e8f99-aacb-41ad-9f83-b2cceebab565/. ahead of the closing date.

Reviews

There are no reviews yet.

Be the first to review “PhD Project in A novel intervention to support myelin regeneration and functional outcomes in Multiple Sclerosis. (Closing Date: 25 Aug 2023”

Your email address will not be published. Required fields are marked *

Shopping Cart